loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Fisogatinib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Fisogatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    2D Structure
    1. Also known as: Blu-554, 1707289-21-1, Blu554, N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide, Blu111362, Fisogatinib [inn]
    Molecular Formula
    C24H24Cl2N4O4
    Molecular Weight
    503.4  g/mol
    InChI Key
    MGZKYOAQVGSSGC-DLBZAZTESA-N
    FDA UNII
    5Q7R99CKV2
    Fisogatinib is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide
    2.1.2 InChI
    InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
    2.1.3 InChI Key
    MGZKYOAQVGSSGC-DLBZAZTESA-N
    2.1.4 Canonical SMILES
    COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)NC4COCCC4NC(=O)C=C)Cl)OC
    2.1.5 Isomeric SMILES
    COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)N[C@@H]4COCC[C@@H]4NC(=O)C=C)Cl)OC
    2.2 Other Identifiers
    2.2.1 UNII
    5Q7R99CKV2
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-propenamide, N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2h-pyran-4-yl)-

    2. Blu-554

    3. N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide

    4. N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide

    2.3.2 Depositor-Supplied Synonyms

    1. Blu-554

    2. 1707289-21-1

    3. Blu554

    4. N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide

    5. Blu111362

    6. Fisogatinib [inn]

    7. Fisogatinib [usan]

    8. X439161

    9. Blu-111362

    10. 5q7r99ckv2

    11. Blu 554

    12. X-439161

    13. 2-propenamide, N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2h-pyran-4-yl)-

    14. N-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide

    15. N-[(3s,4s)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide

    16. Blu554(fisogatinib)

    17. Fisogatinib (usan/inn)

    18. Unii-5q7r99ckv2

    19. Fisogatinib [who-dd]

    20. Blu 554 [who-dd]

    21. Chembl4514636

    22. Schembl16668287

    23. Gtpl10220

    24. Ex-a841

    25. Amy16699

    26. Bdbm50575072

    27. Cs3008

    28. Mfcd30496704

    29. Nsc795718

    30. S8503

    31. Who 10947

    32. Akos030632994

    33. Ccg-269714

    34. Cs-5986

    35. Nsc-795718

    36. Ac-29871

    37. As-55934

    38. Bb160379

    39. Hy-100492

    40. D11737

    41. Q29209801

    42. N-[(3s,4s)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2h-pyran-4-yl]-2-propenamide

    2.4 Create Date
    2015-09-28
    3 Chemical and Physical Properties
    Molecular Weight 503.4 g/mol
    Molecular Formula C24H24Cl2N4O4
    XLogP34.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count7
    Exact Mass502.1174606 g/mol
    Monoisotopic Mass502.1174606 g/mol
    Topological Polar Surface Area94.6 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity688
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Post Enquiry
    POST ENQUIRY